Schematic representation of healthy brain (left) and Alzheimer’s disease (AD) brain (right). Compared to the healthy brain, the brain with AD, as the disease progresses, features an atrophied cerebral cortex, shrinkage of the hippocampus, and enlargement of the ventricles. The AD brain has two other key features: amyloid-beta plaques and tau neurofibrillary tangles (NFTs). Aβ plaques are located extracellularly, and tau NFTs are located intracellularly. These two pathologies are the defining features of AD and are required for a neuropathological diagnosis of AD. This figure is adapted from Breijyeh & Karaman. Molecules 2020;25(24):5789.
The content is licensed under a Creative Commons Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/
Related content
Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.
Overview of how blood-based biomarkers may support screening, diagnosis, staging, prognosis, and treatment decisions across the Alzheimer’s disease continuum.
Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.